Medicare Drug Price Debate May Reemerge After Election, BIO Fears
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech association is comfortable with both presidential candidates, but concerned that they appear to support a heavier government hand in the Part D benefit.